All data generated or analyzed during this study are included in the published articles

Introduction {#sec005}
============

Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver cancer following hepatocellular carcinoma with a stably growing incidence and mortality\[[@pone.0229292.ref001], [@pone.0229292.ref002]\]. Surgical resection is still the most preferred treatment for patients with ICC, but only 15% of patients have the chance of surgery at initial diagnosis\[[@pone.0229292.ref003]--[@pone.0229292.ref005]\]. However, the prognosis of patients with ICC after resection remains far from satisfactory with the 5-year survival rate around 30%\[[@pone.0229292.ref006], [@pone.0229292.ref007]\]. Hence, concerns have always been focused on any strategies intended to improve the prognosis.

Various kinds of adjuvant therapies (AT), such as chemotherapy\[[@pone.0229292.ref008]--[@pone.0229292.ref010]\], radiotherapy\[[@pone.0229292.ref011], [@pone.0229292.ref012]\], transarterial chemoembolization (TACE)\[[@pone.0229292.ref013], [@pone.0229292.ref014]\], and chemoradiotherapy\[[@pone.0229292.ref015]\] have been conducted prevalently to improve the prognosis of patients after resection, and 21.4%-57.7% of patients were reported to receive AT after resection\[[@pone.0229292.ref014], [@pone.0229292.ref016]\]. However, the benefit of AT remains controversial\[[@pone.0229292.ref008], [@pone.0229292.ref009], [@pone.0229292.ref012]\]. Considering that randomized controlled trials or prospective studies evaluating the clinical vale of AT are hard to conduct, a comprehensive systematic review and meta-analysis is needed to confirm it.

Material and method {#sec006}
===================

This study was based on published studies and the informed consent of the patients and the ethical approval were not required. This meta-analysis was conducted according to the preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).

Literature search {#sec007}
-----------------

A comprehensive search on the existing published medical literature was conducted by Qiao Ke and Nanping Lin to investigate the value of the AT for patients with ICC after surgical resection. English electronic databases such as PubMed, MedLine, Embase, the Cochrane Library, Web of Science were used to search the literature from Jan.1^st^ 1990 to Aug. 31^st^ 2019. Key words were as follows: ("intrahepatic cholangiocarcinoma" or "ICC" or "iCCA") AND ("adjuvant therapy" or "transarterial chemoembolization" or "chemotherapy or "radiotherapy" or "chemoradiotherapy"). Any potentially eligible studies were then identified manually through the references of the included studies, reviews, letters and comments.

Selection criteria {#sec008}
------------------

### Inclusion criteria {#sec009}

i\) patients with ICC confirmed by pathology; ii) patients receiving surgical resection; iii) groups must include AT group and non-AT group; iv) outcomes must include the long-term outcomes.

### Exclusion criteria {#sec010}

i\) patients including gallbladder carcinoma or extrahepatic cholangiocarcinoma; ii) patients receiving neoadjuvant therapy; iii) patients receiving palliative resection; ⅳ) data on the long-term outcomes was not available; ⅴ) studies based on overlapping cohorts deriving from the same center; ⅵ) reviews, comments, letters, case report, and conference abstract.

Of note, considering that the data of most of the American studies came from the national cancer data base (NCDB), we only incorporated the study with longest research span if overlapping cohorts existed among studies.

Intervention {#sec011}
------------

Hepatectomy was conducted with or without lymph node dissection\[[@pone.0229292.ref017], [@pone.0229292.ref018]\], regardless of margin status.

AT was defined as any strategies administrated before recurrence, regardless of TACE, chemotherapy, radiotherapy, and chemoradiotherapy.

Data extraction {#sec012}
---------------

Data such as the author's first name, year of publication, study methods, patient's characteristic, interventions, and outcomes were extracted and assessed by Qiao Ke and Nanping Lin with predefined forms. The hazard ratios (HRs) of OS or RFS were extracted directedly from the original data or extracted from the Kaplan-Meier curves according to the methods described in detail by Tierney et al\[[@pone.0229292.ref019]\]. and Parmar et al\[[@pone.0229292.ref020]\]. In case of disagreement, a third investigator, Manjun Deng, was intervened to reach a conclusion.

Quality assessment {#sec013}
------------------

The quality of non-randomized studies was assessed by the modified Newcastle-Ottawa Scale (NOS)\[[@pone.0229292.ref021]\], and more than 7 stars were defined as high quality, 4\~6 star as medium quality, and \<4 stars as low quality.

Statistical analysis {#sec014}
--------------------

The meta-analysis was registered at <http://www.crd.york.ac.uk/PROSPERO/> (Review registry 145810) and was performed using Stata 14. Considering all of the included studies were retrospective cohort studies, endpoints in this meta-analysis were evaluated by HRs and 95%CIs using the random-effects model\[[@pone.0229292.ref022], [@pone.0229292.ref023]\]. Subgroup analyses were conducted in the group of different AT strategies, R1 resection, and lymph node metastasis. Sensitivity analysis was conducted to observe whether the present result would be affected by any one study. Publication bias was determined using Begg's and Egger's tests, and "trim and fill" method was introduced to check the effect of potentially unpublished studies on the present result.

Results {#sec015}
=======

Base characteristic of the included studies {#sec016}
-------------------------------------------

Totally, 1267 records were excluded from the initially identified 1289 records. 22 studies including 23 cohorts and 10181 patients were enrolled in this meta-analysis\[[@pone.0229292.ref009], [@pone.0229292.ref011]--[@pone.0229292.ref014], [@pone.0229292.ref016], [@pone.0229292.ref024]--[@pone.0229292.ref039]\]. Groups were classified as follows: 832 patients in the chemotherapy group, 309 patients in the TACE group, 1192 patients in the radiotherapy group, 235 patients in the chemoradiotherapy group, and 6424 patients in the non-AT group. Of note, both adjuvant chemotherapy and adjuvant chemoradiotherapy were evaluated in Sur's study\[[@pone.0229292.ref033]\], so the former was defined as Sur 2014a and the latter was defined as Sur 2014b. The search strategies and results were shown in [Fig 1](#pone.0229292.g001){ref-type="fig"}.

![PRISMA flow diagram showing selection of articles for meta-analysis.](pone.0229292.g001){#pone.0229292.g001}

The characteristics and baseline demographic data of the patients in each research were listed in [Table 1](#pone.0229292.t001){ref-type="table"}. Of note, two studies were international multi-centers ones\[[@pone.0229292.ref016], [@pone.0229292.ref033]\]. Details of AT in the included studies were depicted in [Table 2](#pone.0229292.t002){ref-type="table"}. NOS score of each included study was exhibited in [Table 3](#pone.0229292.t003){ref-type="table"}, among of which 20 studies were scored 7--9\[[@pone.0229292.ref009], [@pone.0229292.ref011]--[@pone.0229292.ref014], [@pone.0229292.ref016], [@pone.0229292.ref025]--[@pone.0229292.ref037], [@pone.0229292.ref039]\] and two were scored 5--6\[[@pone.0229292.ref024], [@pone.0229292.ref038]\].

10.1371/journal.pone.0229292.t001

###### Basic characteristics of included studies.

![](pone.0229292.t001){#pone.0229292.t001g}

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                          Country         Design          Period       Primary endpoints   Sex(M/F)    LNM(+/-)   Vascular invasion(+/-)   Resection margin(+/-)   Follow-up\
                                                                                                                                                                                          (months)
  ---------------------------------------------- --------------- --------------- ------------ ------------------- ----------- ---------- ------------------------ ----------------------- -------------------
  Roayaie 1998\[[@pone.0229292.ref024]\]         US              Single center   1991--1997   OS/RFS              NR          8/8        NR                       NR                      35.7(0.1--73.2)

  Jan 2005\[[@pone.0229292.ref025]\]             China           Single center   1997--2001   OS                  128/184     NR         NR                       222/90                  14.1(1.05--167.6)

  Jiang 2010\[[@pone.0229292.ref026]\]           China           Single center   1998--2008   OS                  52/38       90/0       NR                       NR                      13.2(0.3--123)

  Shen 2011\[[@pone.0229292.ref027]\]            China           Single center   2002--2003   OS/RFS              88/37       10/115     38/87                    NR                      18(3--96)

  Wu 2012\[[@pone.0229292.ref028]\]              China           Single center   2005--2006   OS                  88/26       11/103     14/100                   NR                      NR

  Ribero 2012\[[@pone.0229292.ref030]\]          Italy           Multi-center    1990--2008   OS                  243/191     113/321    211/223                  NR                      36.5

  Bhudhisawasdi 2012\[[@pone.0229292.ref029]\]   Thailand        Single center   1998--2002   OS                  116/55      NR         145/26                   141/30                  NR

  Li 2013\[[@pone.0229292.ref032]\]              China           Single center   2000--2011   OS/RFS              NR          34/177     51/160                   NR                      NR

  Liu 2013\[[@pone.0229292.ref031]\]             China           Single center   2005--2011   OS                  48/33       50/31      NR                       NR                      NR

  Sur 2014\[[@pone.0229292.ref033]\]             US              Multi-center    1998--2006   OS                  NR          128/510    NR                       180/458                 NR

  Miura 2015\[[@pone.0229292.ref034]\]           US              Multi-center    1998--2011   OS                  NR          NR         NR                       NR                      NR

  Li 2015\[[@pone.0229292.ref014]\]              China           Single center   2008--2011   OS/RFS              368/185     104/449    73/480                   NR                      25.3(2.2--76.2)

  Okumaura 2016\[[@pone.0229292.ref036]\]        Japan           Single center   2004--2015   OS/RFS              67/42       32/77      69/40                    18/91                   NR

  Luvira 2016\[[@pone.0229292.ref035]\]          Thailand        Single center   2004--2009   RFS                 26/24       18/32      NR                       27/23                   NR

  Hammad 2016\[[@pone.0229292.ref012]\]          US              Multi-center    1998--2013   OS                  819/755     607/967    NR                       NR                      NR

  Jeong 2017\[[@pone.0229292.ref013]\]           China           Single center   2011--2015   OS                  28/14       15/27      16/26                    NR                      36(11--65)

  Tran 2017\[[@pone.0229292.ref039]\]            US              Multi-center    2004--2012   OS                  NR          NR         NR                       NR                      NR

  Schweitzer 2017\[[@pone.0229292.ref037]\]      Germany         Single center   2000--2015   OS                  111/86      45/152     44/153                   NR                      NR

  Reames 2017\[[@pone.0229292.ref009]\]          International   Multi-center    1990--2015   OS                  638/516     200/954    217/805                  146/992                 NR

  Zheng 2018\[[@pone.0229292.ref011]\]           China           Single center   2007--2016   OS                  NR          31/18      10/39                    NR                      NR

  Lee 2019\[[@pone.0229292.ref016]\]             US              Multi-center    2004--2014   OS                  1315/1498   582/2231   NR                       649/2164                25.2(13.2--42)

  Sahara 2019\[[@pone.0229292.ref038]\]          International   Multi-center    1990--2015   OS                  NR          NR         NR                       NR                      21.2(11.2--38.9)
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

M: male; F: female; LNM: lymph node metastasis; NR: not report; OS, overall survival; RFS, recurrence-free survival.

10.1371/journal.pone.0229292.t002

###### Interventions of adjuvant treatments in the included studies.

![](pone.0229292.t002){#pone.0229292.t002g}

  Study                                          Treatment types   Patients(yes/no)   Regimens
  ---------------------------------------------- ----------------- ------------------ ---------------------------------------------------------------------------------------------------------
  Roayaie 1998\[[@pone.0229292.ref024]\]         CRT               9/7                5-FU(1000mg/m^2^)+external beam radiotherapy (40-50GY)
  Jan 2005\[[@pone.0229292.ref025]\]             CT                118/194            5-FU+cisplatin+gemcitabine+doxorubicine+oxaliplatin
  Jiang 2010\[[@pone.0229292.ref026]\]           RT                24/66              external beam radiation(50 Gy)
  Shen 2011\[[@pone.0229292.ref027]\]            TACE              53/72              5-FU (500 mg)/ carboplatin (100 mg)+iodized oil (3--5ml)+epirubicin (20 mg)+hydroxycamptothecin (10 mg)
  Wu 2012\[[@pone.0229292.ref028]\]              TACE              57/57              5-FU (500 mg)/ carboplatin (100 mg)+iodized oil (3--5ml)+epirubicin (20 mg)+hydroxycamptothecin (10 mg)
  Ribero 2012\[[@pone.0229292.ref030]\]          CT                116/318            NR
  Bhudhisawasdi 2012\[[@pone.0229292.ref029]\]   CT                54/117             5-FU(1000mg/m^2^)+mitomycin C(10mg/m^2^)
  Li 2013\[[@pone.0229292.ref032]\]              TACE              68/143             5-FU(500 mg)+iodized oil(3--5 ml)+epirubicin (20 mg)+hydroxycamptothecin (10 mg)
  Liu 2013\[[@pone.0229292.ref031]\]             CT                18/63              5-FU+cisplatin+gemcitabine+doxorubicine+oxaliplatin
  Sur 2014a\[[@pone.0229292.ref033]\]            CT                75/416             NR
  Sur 2014b\[[@pone.0229292.ref033]\]            CRT               147/416            NR
  Miura 2015\[[@pone.0229292.ref034]\]           RT                486/77             NR
  Li 2015\[[@pone.0229292.ref014]\]              TACE              122/431            5-FU(500 mg)+iodized oil(3--5 ml)+epirubicin (20 mg)+hydroxycamptothecin (10 mg)
  Okumaura 2016\[[@pone.0229292.ref036]\]        CT                47/62              Gemcitabine+ S-1
  Luvira 2016\[[@pone.0229292.ref035]\]          CT                18/32              5-FU(1000mg/m^2^)+mitomycin C(10mg/m^2^)
  Hammad 2016\[[@pone.0229292.ref012]\]          RT                525/1049           NR
  Jeong 2017\[[@pone.0229292.ref013]\]           TACE              9/33               5-FU+epirubicin+cisplatin
  Tran 2017\[[@pone.0229292.ref039]\]            CRT               79/170             NR
  Schweitzer 2017\[[@pone.0229292.ref037]\]      CT                39/158             gemcitabine (1000 mg/m^2^)+cisplatin (25mg/m^2^)+oxaliplatin (100mg/m^2^)
  Reames 2017\[[@pone.0229292.ref009]\]          CT                347/807            gemcitabine (1000 mg/m^2^)+cisplatin (25mg/m^2^)+oxaliplatin (100mg/m^2^)
  Zheng 2018\[[@pone.0229292.ref011]\]           RT                26/23              intensity-modulated radiotherapy(50-60Gy)
  Lee 2019\[[@pone.0229292.ref016]\]             CT/CRT            1189/1624          NR
  Sahara 2019\[[@pone.0229292.ref038]\]          RT                131/505            NR

CRT: chemoradiotherapy; CT: chemotherapy; RT: radiotherapy; TACE, transarterial chemoembolization; NR: not report.

10.1371/journal.pone.0229292.t003

###### Newcastle-Ottawa quality assessment of the included studies.
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  Study                                          Selection   Comparability   Outcome                                            
  ---------------------------------------------- ----------- --------------- --------- ------- -------- ------- ------- ------- ---
  Roayaie 1998\[[@pone.0229292.ref024]\]         **★**                                 **★**   **★**    **★**   **★**           5
  Jan 2005\[[@pone.0229292.ref025]\]             **★**       **★**           **★**     **★**   **★**    **★**   **★**   **★**   8
  Jiang 2010\[[@pone.0229292.ref026]\]           **★**       **★**           **★**             **★**    **★**   **★**   **★**   7
  Shen 2011\[[@pone.0229292.ref027]\]            **★**       **★**           **★**     **★**   **★**            **★**   **★**   7
  Wu 2012\[[@pone.0229292.ref028]\]              **★**       **★**           **★**             **★★**   **★**   **★**   **★**   8
  Ribero 2012\[[@pone.0229292.ref030]\]          **★**       **★**           **★**             **★**    **★**   **★**   **★**   7
  Bhudhisawasdi 2012\[[@pone.0229292.ref029]\]   **★**       **★**           **★**     **★**            **★**   **★**   **★**   7
  Li 2013\[[@pone.0229292.ref032]\]              **★**       **★**           **★**     **★**   **★★**   **★**   **★**   **★**   9
  Liu 2013\[[@pone.0229292.ref031]\]             **★**       **★**           **★**     **★**   **★**    **★**   **★**   **★**   8
  Sur 2014\[[@pone.0229292.ref033]\]             **★**       **★**           **★**             **★**    **★**   **★**   **★**   7
  Miura 2015\[[@pone.0229292.ref034]\]           **★**       **★**           **★**     **★**   **★**    **★**   **★**   **★**   8
  Li 2015\[[@pone.0229292.ref014]\]              **★**       **★**           **★**     **★**   **★★**   **★**   **★**   **★**   9
  Okumaura 2016\[[@pone.0229292.ref036]\]        **★**       **★**           **★**     **★**   **★**    **★**   **★**   **★**   8
  Luvira 2016\[[@pone.0229292.ref035]\]          **★**       **★**                     **★**   **★**    **★**           **★**   6
  Hammad 2016\[[@pone.0229292.ref012]\]          **★**       **★**           **★**     **★**   **★**    **★**   **★**   **★**   8
  Jeong 2017\[[@pone.0229292.ref013]\]           **★**       **★**           **★**     **★**            **★**   **★**   **★**   7
  Tran 2017\[[@pone.0229292.ref039]\]            **★**       **★**           **★**     **★**   **★**    **★**   **★**   **★**   8
  Schweitzer 2017\[[@pone.0229292.ref037]\]      **★**       **★**           **★**     **★**   **★**    **★**   **★**   **★**   8
  Reames 2017\[[@pone.0229292.ref009]\]          **★**       **★**           **★**     **★**   **★★**   **★**   **★**   **★**   9
  Zheng 2018\[[@pone.0229292.ref011]\]           **★**       **★**           **★**     **★**   **★**    **★**   **★**   **★**   8
  Lee 2019\[[@pone.0229292.ref016]\]             **★**       **★**           **★**     **★**   **★**    **★**   **★**   **★**   8
  Sahara 2019\[[@pone.0229292.ref038]\]          **★**       **★**           **★**     **★**            **★**           **★**   6

Endpoints {#sec017}
---------

The OS and RFS comparing between AT group and non-AT group were evaluated in 22\[[@pone.0229292.ref009], [@pone.0229292.ref011]--[@pone.0229292.ref014], [@pone.0229292.ref016], [@pone.0229292.ref024]--[@pone.0229292.ref034], [@pone.0229292.ref036]--[@pone.0229292.ref039]\] and 6 included cohorts \[[@pone.0229292.ref014], [@pone.0229292.ref024], [@pone.0229292.ref027], [@pone.0229292.ref032], [@pone.0229292.ref035], [@pone.0229292.ref036]\], respectively. Using a random-effect model, the pooled HR for the OS and RFS in the AT group were 0.63 (95%CI 0.52\~0.74, [Fig 2A](#pone.0229292.g002){ref-type="fig"}), and 0.74 (95%CI 0.58\~0.90, [Fig 2B](#pone.0229292.g002){ref-type="fig"}), respectively, compared with the non-AT group.

![Forest plot of the overall survival and recurrence-free survival rates between adjuvant therapy and operation only.\
A, overall survival; B, recurrence-free survival.](pone.0229292.g002){#pone.0229292.g002}

Subgroup analysis stratified by different AT strategies {#sec018}
-------------------------------------------------------

The OS and RFS comparing between adjuvant chemotherapy group and non-AT group were evaluated in 9\[[@pone.0229292.ref009], [@pone.0229292.ref025], [@pone.0229292.ref029]--[@pone.0229292.ref031], [@pone.0229292.ref033], [@pone.0229292.ref036]--[@pone.0229292.ref038]\] and 2\[[@pone.0229292.ref035], [@pone.0229292.ref036]\] included cohorts, respectively. Using a random-effect model, the pooled HR for the OS and RFS in the AT group were 0.57 (95%CI 0.44\~0.70, [Fig 3A](#pone.0229292.g003){ref-type="fig"}), and 0.75 (95%CI 0.45\~1.05, [Fig 3B](#pone.0229292.g003){ref-type="fig"}), respectively, compared with the non-AT group.

![Forest plot of the overall survival and recurrence-free survival rates between adjuvant chemotherapy and operation only.\
A, overall survival; B, recurrence-free survival.](pone.0229292.g003){#pone.0229292.g003}

The OS and RFS comparing between adjuvant TACE group and non-AT group were evaluated in 5\[[@pone.0229292.ref013], [@pone.0229292.ref014], [@pone.0229292.ref027], [@pone.0229292.ref028], [@pone.0229292.ref032]\] and 3\[[@pone.0229292.ref014], [@pone.0229292.ref027], [@pone.0229292.ref032]\] included cohorts, respectively. Using a random-effect model, the pooled HR for the OS and RFS in the adjuvant TACE group were 0.56 (95%CI 0.31\~0.82, [Fig 4A](#pone.0229292.g004){ref-type="fig"}), and 0.74 (95%CI 0.55\~0.93, [Fig 4B](#pone.0229292.g004){ref-type="fig"}), respectively, compared with the non-AT group.

![Forest plot of the overall survival and recurrence-free survival rates between adjuvant TACE and operation only.\
A, overall survival; B, recurrence-free survival.](pone.0229292.g004){#pone.0229292.g004}

The OS comparing between adjuvant radiotherapy group or adjuvant chemoradiotherapy group and non-AT group were evaluated in 4\[[@pone.0229292.ref011], [@pone.0229292.ref012], [@pone.0229292.ref026], [@pone.0229292.ref034]\] and 3\[[@pone.0229292.ref024], [@pone.0229292.ref033], [@pone.0229292.ref039]\] included cohorts, respectively. Using a random-effect model, the pooled HR for the OS in the adjuvant radiotherapy group and adjuvant chemoradiotherapy group were 0.71 (95%CI 0.39\~1.03, [Fig 5A](#pone.0229292.g005){ref-type="fig"}), and 0.73 (95%CI 0.57\~0.89, [Fig 5B](#pone.0229292.g005){ref-type="fig"}), respectively, compared with the non-AT group.

![Subgroup analysis of OS stratified by adjuvant radiotherapy and chemoradiotherapy.\
A, adjuvant radiotherapy; B, adjuvant chemoradiotherapy.](pone.0229292.g005){#pone.0229292.g005}

Subgroup analysis stratified by high risk factors {#sec019}
-------------------------------------------------

The effect of AT on the patients with positive resection margin was evaluated in 4 included cohorts \[[@pone.0229292.ref016], [@pone.0229292.ref024], [@pone.0229292.ref025], [@pone.0229292.ref029]\]. Using a random-effect model, the pooled HR for the OS in the AT group was 0.60 (95%CI 0.51\~0.69, [Fig 6A](#pone.0229292.g006){ref-type="fig"}), compared with the non-AT group. The effect of AT on the patients with LNM was evaluated in 4 included cohorts \[[@pone.0229292.ref009], [@pone.0229292.ref016], [@pone.0229292.ref024], [@pone.0229292.ref026]\]. Using a random-effect model, the pooled HR for the OS in the AT group was 0.67 (95%CI 0.57\~0.76, [Fig 6B](#pone.0229292.g006){ref-type="fig"}), compared with the non-AT group.

![Subgroup analysis stratified by high risk factors.\
A, positive resection margin; B. lymph node metastasis.](pone.0229292.g006){#pone.0229292.g006}

Sensitivity analysis {#sec020}
--------------------

Sensitivity analysis was conducted in the primary endpoint comparing between AT group and non-AT group, and result showed that the pooled HR for the OS in the AT group did not change substantially after any study was removed compared with the non-AT group ([Fig 7](#pone.0229292.g007){ref-type="fig"}), which indicated that the present results in this study were robust.

![Sensitivity analysis for overall survival in the included studies.](pone.0229292.g007){#pone.0229292.g007}

Publication bias analysis {#sec021}
-------------------------

Publication bias analysis was conducted in the primary endpoint comparing between AT group and non-AT group. Asymmetry was observed in the funnel plot ([Fig 8](#pone.0229292.g008){ref-type="fig"}) with significant publication bias in the egger's test (p = 0.004) but not in the Begg's test (p = 0.09). "Trim and fill" analysis was then conducted, and 5 more studies were found to be potentially unpublished. The adjusted HR for the OS in the AT group was 0.73 (95%CI 0.63--0.85), compared with the non-AT group, indicating that the present result could not be affected by the unpublished studies.

![Funnel plot of overall survival in the included studies.](pone.0229292.g008){#pone.0229292.g008}

Discussion {#sec022}
==========

The prognosis of patients with ICC after resection is still poor\[[@pone.0229292.ref005], [@pone.0229292.ref006]\], but the benefit of AT has always been questioned in clinical partly because the natural life span is too short and most of the patients have lost the chance of resection at diagnosis\[[@pone.0229292.ref003], [@pone.0229292.ref004]\]. Currently, with the advocation of LND and development of extended resection\[[@pone.0229292.ref040]--[@pone.0229292.ref042]\], the clinical value of AT should be re-evaluated. This is the first systematic review evaluating the clinical value of AT in the treatment of ICC comprehensively, which included 22 studies with 10181 patients, and results showed that patients could be benefited from AT in a whole. However, in our opinion, identifying the selected patients and choosing the appropriate AT strategy are the keys.

Chemotherapy is first to be administrated in the postoperative adjuvant treatments of ICC, and adjuvant chemotherapy is still the most preferred strategy in clinical up to now with the reported incidence as high as 46.6%\[[@pone.0229292.ref015]\]. However, the benefit of chemotherapy has been always been questioned mainly because cholangiocarcinoma is not sensitive to chemotherapeutics\[[@pone.0229292.ref043]\]. In this meta-analysis, adjuvant chemotherapy was confirmed to be associated with improved OS, which was coincident with the previous meta-analysis\[[@pone.0229292.ref010], [@pone.0229292.ref044]\]. In addition, Gemcitabine-based chemotherapy was confirmed to be superior to 5-Fu based chemotherapy in the improvement of prognosis\[[@pone.0229292.ref010], [@pone.0229292.ref044]\].

TACE is conducted widely in the management of ICC, such as adjuvant therapy for patients receiving resection\[[@pone.0229292.ref013], [@pone.0229292.ref014]\], and palliative treatment for unresectable ICC\[[@pone.0229292.ref045], [@pone.0229292.ref046]\]. However, someone argued the benefit of adjuvant TACE for ICC\[[@pone.0229292.ref027]\], mainly because ICC could metastasize specifically through lymph node. To the best of our knowledge, this is the first meta-analysis confirming the benefit of adjuvant TACE. Reasons are mainly due to that most of the recurrences are still intrahepatic ones\[[@pone.0229292.ref047]\], but it deserves further validation.

Radiotherapy is playing an increasing important role in the management of ICC with the development of stereotactic body radiotherapy\[[@pone.0229292.ref011]\]. From the other hand, metastatic lymph node is much more sensitive to radiotherapy\[[@pone.0229292.ref012]\]. However, the benefit of radiotherapy was not confirmed in this meta-analysis, which deserved our deep rethink. In addition, chemoradiotherapy is being more and more preferred in clinical, because synergistic effect is believed to between radiotherapy and chemotherapy\[[@pone.0229292.ref015]\]. This is the first meta-analysis identifying the benefit of adjuvant chemoradiotherapy, but either sequential or concurrent chemoradiotherapy deserves further study.

As is known to all, one size does not fit all, so identifying the selected patients who could be benefited from AT is also a big deal. Adjuvant chemotherapy and TACE are found to only benefit patients with "high risk", such as positive margins\[[@pone.0229292.ref024], [@pone.0229292.ref029]\], LNM\[[@pone.0229292.ref048]\], and advanced stages\[[@pone.0229292.ref016]\], but as for radiotherapy it is hard to say. Zheng et al\[[@pone.0229292.ref011]\] found that adjuvant radiotherapy could benefit patients with narrow surgical margin, but Hammad et al\[[@pone.0229292.ref012]\] reported that adjuvant radiotherapy could only improve the prognosis of patients with R0 resection rather than those with R1 resection and LNM. Hence, who would be benefited from AT, either with high risk or with low risk, is still a puzzle.

In the recent decades, pathway-targeted therapies made a rapid progress in solid tumors\[[@pone.0229292.ref049], [@pone.0229292.ref050]\]. Previous studies found that approximately 30%\~40% of ICC patients exhibited actionable mutations, such as epidermal growth factor receptor (EGFR), and fibroblast growth factor receptor (FGFR) which shed light on the molecular targeted therapies on ICC\[[@pone.0229292.ref051], [@pone.0229292.ref052]\]. From the other hand, next-generation and exome sequencing studies found that 10%\~15% of cholangiocarcinoma patients had DNA repair mutations\[[@pone.0229292.ref053]\], and 40% of cholangiocarcinoma patients had positive programmed cell death receptor 1 (PDL1) expression\[[@pone.0229292.ref054]\], who might be the potential beneficiaries of immunotherapies. Recent clinical trials have exhibited promising results in the advanced cholangiocarcinoma, which would change the trajectory of ICC management\[[@pone.0229292.ref055], [@pone.0229292.ref056]\]. In future, promises of adjuvant targeted therapies and/or immunotherapies have been expected in the on-going trials.

There were several restrictions of this meta-analysis. First, all the included studies were retrospective ones, indicating an obvious selection and recalling bias. Second, most of the studies were multi-centers or based on the database mainly due to the rare incidence of ICC, which meant that procedure of surgical resection and AT were different and bias was hard to avoid. Third, most of the cofounding factors such as radical resection and LNM were hard to be resorted in the original studies, which would weaken the conclusion. Fourth, RFS was evaluated in only six of the 22 included studies, which was insufficient to evaluate the effect of AT on recurrence. Fifth, considering that the span of the included studies was a little longer (1990\~2019), during which the surgical techniques, chemotherapy agents and radiation approaches were different, our conclusion in this study deserved further validation. The last but not the least, publication bias was found in this meta-analysis, although the present result was found to be not changed after "trim and fill" analysis.

Conclusion {#sec023}
==========

With the current data, we concluded that AT would benefit patients with ICC after resection, but it deserved further validation. Considering that not all AT strategies would bring benefit to patients with ICC, and not all patients would be benefited from AT, identifying the potential beneficiaries of different AT is a priority in future.
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